Angelini Pharma is the pharmaceutical division of Angelini Industries. The Group started almost 100 years ago as a small pharmaceutical laboratory, and over the years has grown into a leading international group in healthcare, present in Pharmaceuticals and Mass-Market.
Angelini Pharma is a leader in healthcare, with particular strength and expertise in the fields of Mental Health and Epilepsy. The company is also a leading player in the Consumer Health segment, with highly successful OTC brands worldwide.
Angelini Pharma products are marketed in about 70 countries. The company operates directly in 20 countries employing almost 3.000 people, and commercializes its products in more than 70 countries through strategic alliances with leading international pharmaceutical groups.
As part of its internationalisation strategy, Angelini Pharma has also concentrated on development in countries with high growth potential.
Angelini Pharma reported a turnover of €1,2 billion in 2022, about half accounted for by exports.
Angelini Pharma is an integrated pharmaceutical company, with an extensive R&D operation that has developed important molecules such as trazodone and benzydamine.
Current research focuses on Nervous System Diseases and Disorders and Pain and Inflammation, with a particular commitment to the research of new treatments for the paediatric population.
The research embraces public-private partnerships with recognised academic institutions and centres of global importance. The Scientific Network and Partnerships both have an important role in creating innovation.
Angelini Pharma's “world class” production plants use cutting-edge technologies and have full certification for quality standards and respect for the environment.
In Italy, finished pharmaceutical products are produced in the Ancona plant, while the industrial factory in Aprilia produces pharmaceutical raw materials. Disinfectants and sanitising products under the Amuchina brand are produced in Casella. These sites make extensive use of renewable energy sources and meet criteria of sustainability. Finally, the Albany (Georgia, USA) plant produces self-heating wraps under the ThermaCare® brand and the Barcelona plant (Spagna) produces food supplements such as Pastillas Juanola.
Turnover €1,2 billion
Angelini Pharma turnover more than tripled between 2000 and 2022, from €240.8M to €1,2 billion
Employees 3000 people
More than 120 researchers and 1,000 people in sales
Presence 70 Countries
Our products are marketed in about 70 countries. Direct presence in 20 countries.